Why Novavax Was Tumbling by 12% This Week
The coronavirus might be surging in various parts of the world, but this hasn't made coronavirus stock Novavax (NASDAQ: NVAX) a compelling buy lately. Data provided by S&P Global Market Intelligence reveal that the company's shares were down by just under 12% week to date as of Thursday's stock market close.
Novavax has been somewhat of a perennial laggard in what was once a compelling race to bring a coronavirus vaccine to market. As fellow COVID jab developers like Moderna and the partnership of Pfizer and Germany-based biotech BioNTech were winning authorizations for their products from major regulators, Novavax was still getting its act together with formal submissions.
Image source: Getty Images.
Source Fool.com
